MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.18
+0.64
+5.55%
After Hours: 12.55 +0.37 +3.04% 19:57 06/11 EDT
OPEN
13.06
PREV CLOSE
11.54
HIGH
13.73
LOW
12.02
VOLUME
7.43M
TURNOVER
--
52 WEEK HIGH
70.29
52 WEEK LOW
9.53
MARKET CAP
849.55M
P/E (TTM)
-13.3057
1D
5D
1M
3M
1Y
5Y
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to ...
Benzinga · 2d ago
ChemoCentryx continues winning streak amid looming legal challenge
syahrir maulana/iStock via Getty Images Despite a loss of ~81.4% in the year so far, ChemoCentryx ([[CCXI]] +5.5%) is on course to record its sixth straight session of gains today.
Seekingalpha · 2d ago
Thinking about buying stock in Novan, Chemomab Therapeutics, Precigen, ChemoCentryx, or Senseonics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, CMMB, PGEN, CCXI, and SENS.
PR Newswire - PRF · 2d ago
Healthcare names dominate premarket gainers
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor
Seekingalpha · 2d ago
ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
ChemoCentryx (CCXI) announces presentations highlighting outcomes of its Phase III ADVOCATE trial and Phase II ACCOLADE and LUMINA-1 trials as part of the annual meeting of the ERA-EDTA, held virtually
Seekingalpha · 5d ago
ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress
-- Abstract on 'The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease' honored on "Ten Best" list by the Paper Selection Committee of ERA-EDTA --
GlobeNewswire · 5d ago
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for ChemoCentryx, Inc. Investors
Radnor, Pennsylvania--(Newsfile Corp. - June 7, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against ChemoCentryx, Inc. (NASDAQ: CCXI) ("ChemoCentryx") on behalf of...
Newsfile · 6d ago
CCXI Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for ChemoCentryx, Inc. Investors
RADNOR, PA / ACCESSWIRE / June 1, 2021 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of ChemoCentryx, Inc. (NASDAQ:CCXI) ("ChemoCentryx") that a securities fraud class action lawsuit has been filed against on behalf of those who pu...
ACCESSWIRE · 06/01 23:44
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CCXI. Analyze the recent business situations of ChemoCentryx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CCXI stock price target is 40.75 with a high estimate of 79.00 and a low estimate of 17.00.
EPS
Institutional Holdings
Institutions: 251
Institutional Holdings: 57.11M
% Owned: 81.88%
Shares Outstanding: 69.75M
TypeInstitutionsShares
Increased
69
3.75M
New
13
173.71K
Decreased
74
4.22M
Sold Out
24
873.95K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.92%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/Director/IR Contact Officer
Susan Kanaya
Chief Operating Officer/Executive Vice President
Tausif Butt
Treasurer
Markus Cappel
Lead Director/Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Rita Jain
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
No Data
  • All
  • Financials
  • Insiders
More
About CCXI
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.